专利检索_ 氨基甲酸衍生物即含有如下任何基团的化合物<img id="id" src="$path$/3399115454/jpggifpegjpeg"/><img id="id" src="$path$/3399115456/jpggifpegjpeg"/>或者<img id="id" src="$path$/3399115458/jpggifpegjpeg"/> 氮原子不属于硝基或亚硝基专利检索_ 氨基甲酸衍生物即含有如下任何基团的化合物<img id="id" src="$path$/3399115454/jpggifpegjpeg"/><img id="id" src="$path$/3399115456/jpggifpegjpeg"/>或者<img id="id" src="$path$/3399115458/jpggifpegjpeg"/> 氮原子不属于硝基或亚硝基专利检索查询_ 氨基甲酸衍生物即含有如下任何基团的化合物<img id="id" src="$path$/3399115454/jpggifpegjpeg"/><img id="id" src="$path$/3399115456/jpggifpegjpeg"/>或者<img id="id" src="$path$/3399115458/jpggifpegjpeg"/> 氮原子不属于硝基或亚硝基专利检索查询分析平台

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	制备芳基－亚氨甲基－氨基甲酸酯的方法	CN200410033549.7	2001-01-11	CN1255378C	2006-05-10	乔尔格·布兰登堡; 雷纳·索伊卡; 罗尔夫·施密德; 拉尔夫·安德斯凯维茨; 罗尔夫·鲍尔; 雷纳·哈姆; 朱塔·克罗伯
本发明是有关工业规模使用的制备通式(I)化合物的方法其中基团R1和R2具有本说明书和权利要求中所定含义。
2	制备芳基－亚氨甲基－氨基甲酸酯的方法	CN01803728.3	2001-01-11	CN1187322C	2005-02-02	乔尔格·布兰登堡; 雷纳·索伊卡; 罗尔夫·施密德; 拉尔夫·安德斯凯维茨; 罗尔夫·鲍尔; 雷纳·哈姆; 朱塔·克罗伯
本发明是有关工业规模使用的制备通式(I)化合物的方法其中基团R1和R2具有本说明书和权利要求中所定含义。
3	制备芳基－亚氨甲基－氨基甲酸酯的方法	CN01803728.3	2001-01-11	CN1395557A	2003-02-05	乔尔格·布兰登堡; 雷纳·索伊卡; 罗尔夫·施密德; 拉尔夫·安德斯凯维茨; 罗尔夫·鲍尔; 雷纳·哈姆; 朱塔·克罗伯
本发明是有关工业规模使用的制备通式(I)化合物的方法其中基团R1和R2具有本说明书和权利要求中所定含义。
4	用于治疗多发性硬化症的组合物和方法	CN201380027236.8	2013-05-16	CN104603097A	2015-05-06	M·坎杜拉
本发明涉及式I和式II的化合物或其可药用的盐、以及多晶型物、溶剂化物、对映异构体、立体异构体和水合物。可以配制包含有效量的式I或式II的化合物的药物组合物以及制定治疗或预防多发性硬化症的方法，用于口腔、颊部、直肠、局部、经皮、透粘膜、静脉内、肠胃外施药、糖浆或注射。此类组合物可以用于治疗神经退化性疾病和其他神经炎性疾病。
5	制备芳基－亚氨甲基－氨基甲酸酯的方法	CN200410033549.7	2001-01-11	CN1541999A	2004-11-03	乔尔格·布兰登堡; 雷纳·索伊卡; 罗尔夫·施密德; 拉尔夫·安德斯凯维茨; 罗尔夫·鲍尔; 雷纳·哈姆; 朱塔·克罗伯
本发明是有关工业规模使用的制备通式(I)化合物的方法其中基团R1和R2具有本说明书和权利要求中所定含义。
6	多発性硬化症の治療のための組成物および方法	JP2015513319	2013-05-16	JP2015518854A	2015-07-06	カンデュラ，マヘシュ
本発明は、式Iおよび式IIまたはその薬学的に許容される塩の化合物、ならびに多形体、溶媒和物、鏡像異性体、立体異性体および水和物に関する。式Iまたは式IIの化合物の有効量を含む医薬組成物。多発性硬化症を治療または予防するための方法は、経口、口腔、直腸、局所、経皮、経粘膜、静脈内、非経口投与、シロップ剤、または注射用に製剤化することができる。このような組成物は、神経変性疾患および他の神経炎症性疾患の治療に使用することができる。
7	Aryl - iminomethyl - a process for the preparation of carbamino acid ester	JP2001551839	2001-01-11	JP2003523328A	2003-08-05	ラルフアンデルスケヴィッツ; ユッタクレーバー; ロルフシュミット; ライナーソイカ; ロルフバウアー; ライナーハム; イェルクブランデンブルク
(57)【要約】本発明は式(I) 【化１】（式中、基R ¹及びR ²は明細書及び特許請求の範囲に示された意味を有する）の化合物の製造方法に関するものであり、この方法は大規模で使用し得る。
8	JPS6021133B2 -	JP14351976	1976-12-01	JPS6021133B2	1985-05-25	SUAMI TETSUO; OGAWA SEIICHIRO

9	Anilide derivatives as antidepressants	US930690	1978-08-03	US4217362A	1980-08-12	Jacob Szmuszkovicz
Anilide derivative compounds of the formula ##STR1## e.g., trans-N-(2-hydroxycyclopentyl)-3',4'-dichloropropionanilide, have been found to possess potent Central Nervous System (CNS) antidepressant properties.These compounds are promising antidepressant drugs which are characterized by less toxicity than imipramine, and long-acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are also disclosed.
10	N-(2-Aminocyclopentyl)-N-acylanilides as CNS anti-depressants	US906429	1978-05-15	US4159340A	1979-06-26	Jacob Szmuszkovicz
N-(2-Aminocyclopentyl)-N-acylanilides and their 2-N-oxides of the formula ##STR1## e.g., trans-3,4-dichloro-N-[2-(N-allylamino)cyclopentyl]propionanilide, and their pharmacologically acceptable salts have been found to possess potent Central Nervous System anti-depressant properties. Many of them are new.These compounds are promising anti-depressant drugs which are characterized by a better therapeutic ratio than imipramine, and long acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are disclosed.
11	N-(2-Aminocyclopentyl) alkanoylanilides	US879378	1978-02-21	US4156733A	1979-05-29	Jacob Szmuszkovicz
N-(2-Aminocyclopentyl)N-alkanoylanilides and their 2-N-oxides of the formula ##STR1## e.g., trans-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]propionanilide, and their pharmacologically acceptable salts, have been found to possess potent Central Nervous System anti-depressant properties. Many of them are new.These compounds are promising anti-depressant drugs which are characterized by a better therapeutic ratio than imipramine, and long acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are disclosed.
12	N-(2-aminocyclopentyl)alkanoylanilides	US895210	1978-04-10	US4148913A	1979-04-10	Jacob Szmuskovicz
N-(2-Aminocyclopentyl)N-alkanoylanilides and their 2-N-oxides of the formula ##STR1## e.g., trans-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]propionanilide, and their pharmacologically acceptable salts, have been found to possess potent Central Nervous System anti-depressant properties. Many of them are new.These compounds are promising anti-depressant drugs which are characterized by a better therapeutic ratio than imipramine, and long acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are disclosed.
13	아미드 화합물을 포함하는 전해질 및 이를 구비한 전기화학소자	KR1020110004356	2011-01-17	KR1020110084131A	2011-07-21	이병배; 오재승; 이상현; 최권영; 김동수; 홍연숙; 이효진
PURPOSE: Electrolyte comprising an amide compound is provided to ensure excellent thermal stability, chemical stability, low viscosity, and excellent ion conductivity as well as improved oxidative stability to raise the upper limit value of an electrochemical window. CONSTITUTION: An electrolyte comprises: an amide compound which is represented by chemical formula 1 and, in which an alkoxy alkyl group is substituted by an amine group and a halogen is included; and ionizable lithium salts. In the electrolyte, the molar ratio of the amide compound and lithium salts is 1-8 : 1. The electrochemical window of the electrolyte is 0.4-5.0 V, viscosity is 200cP or less, and ion conductivity is 1-3 mS/cm.
14	Phenylpyridyl compounds for inhibiting phosphodiesterase IV and methods of using same	US875487	1997-11-13	US06153630A	2000-11-28	David J. Cavalla; Mark Chasin; Lloyd Dolby
Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds possess improved PDE IV inhibition as compared to theophylline or rolipram as well as with improved selectivity with regard to PDE III inhibition. In certain aspects of the invention, the compounds also demonstrate PDE V inhibition. Pharmaceutical compositions containing the same and methods of treatment are also disclosed.
15	Phenylcarbamates, processes and intermediate products for their preparation and their use as pesticides and fungicides	US51979	1998-04-23	US6075049A	2000-06-13	Bernd Muller; Hubert Sauter; Herbert Bayer; Wassilios Grammenos; Thomas Grote; Reinhard Kirstgen; Klaus Oberdorf; Franz Rohl; Norbert Gotz; Michael Rack; Ruth Muller; Gisela Lorenz; Eberhard Ammermann; Siegfried Strathmann; Volker Harries
Phenylcarbamates of the formula I ##STR1## where the substituents and the index have the following meanings: R is cyano, nitro, trifluoromethyl, halogen, alkyl or alkoxy;m is 0, 1 or 2;R.sup.1 is alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl, and, in the event that X is NR.sup.a, additionally hydrogen;X is a direct bond, O or NR.sup.a ;R.sup.a is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl;R.sup.2 is hydrogen,substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, alkylcarbonyl or alkoxycarbonyl;R.sup.3 and R.sup.4 independently of one another are hydrogen, cyano, nitro, hydroxyl, amino, halogen, hetaryloxy, hetarylthio, hetarylamino or N-hetaryl-N-alkylamino, andR.sup.5 is one of the groups mentioned under R.sup.3 or a group CR.sup.d .dbd.NOR.sup.e ;processes and intermediates for their preparation, and their use.
16	Heterocyclic compounds for inhibiting phosphodiesterase IV	US716902	1996-09-20	US5889014A	1999-03-30	David John Cavalla; Lloyd J. Dolby; Mark Chasin
Novel compounds which are effective PDE IV inhibitors are disclosed. The compounds have the formula: ##STR1## wherein: R.sub.1 and R.sub.2 may be the same or different and each is selected from the group consisting of hydrogen, saturated or unsaturated straight-chain or branched C.sub.1-12 alkyl groups, cycloalkyl and cycloalkyl-alkyl groups containing from 3 to 10 carbon atoms in the cycloalkyl moiety;R.sub.3 is hydrogen, halogen, or a saturated or unsaturated straight-chain or branched C.sub.1-12 alkyl group, a cycloalkyl and cycloalkyl-alkyl groups containing from 3 to 7 carbon atoms in the cycloalkyl moiety;R.sub.4 is a phenyl or benzyl or a 6-membered heteroaryl which may be unsubstituted or substituted with one or more halogen atoms, alkyl groups, nitro groups, hydroxyl groups, cyano groups, carboxyl groups, alkoxy group, alkoxycarbonyl, amido, carboxamido, substituted or unsubstituted amino groups, cycloalkyl and cycloalkyl-alkyl groups containing from 3 to 10 carbon atoms in the cycloalkyl moiety, aryl or aralkyl groups preferably containing from about 6 to about 10 carbon atoms, or heterocyclic groups containing nitrogen, oxygen or sulfur in the ring; said alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, and arylalkyl groups being unsubstituted or substituted by halogen atoms, hydroxyl groups, cyano groups, carboxyl groups, alkoxy groups, alkoxycarbonyl, carboxamido or substituted or unsubstituted amino groups, or one or more lower alkyl groups having from 1 to 3 carbon atoms;Z is selected from the group consisting of --CH.sub.2 CO--, --NHCH.sub.2 --, --CH.sub.2 NH--, --CH.sub.2 CONH--, --CH.sub.2 NHCO--, --CH.sub.2 COCH.sub.2 --, --COCH.sub.2 --, --C(.dbd.NOC(.dbd.O)NHQ)--, and --C(.dbd.NQ)NH--;X.sub.1 and X.sub.2 may be the same or different and each is O or S;wherein Q is R.sub.4 or hydrogen except that when Z.dbd.C(.dbd.NOCONHQ)--, R.sub.4 is not benzyl and R.sub.1 and R.sub.2 are both not hydrogen.
17	N-(2-Aminocyclopentyl)acylanilides and treating depression	US879379	1978-02-21	US4157398A	1979-06-05	Jacob Szmuszkovicz
N-(2-Aminocyclopentyl)N-alkanoylanilides and their 2-N-oxides of the formula ##STR1## e.g., trans-3,4-dichloro-N-[2-(dimethylamino)cyclopentyl]propionanilide, and their pharmacologically acceptable salts, have been found to possess potent Central Nervous System anti-depressant properties. Many of them are new.These compounds are promising anti-depressant drugs which are characterized by a better therapeutic ratio than imipramine, and long acting activity which may allow longer durations between administrations, e.g., once a day. Pharmaceutical compositions containing these compounds and a process for treating conditions of depression with these compositions are disclosed.
18	Hidden polyisocyanates	US42020454	1954-03-31	US2797232A	1957-06-25	WILHELM BUNGE

19	Process for producing carbamates, process for producing isocyanates, carbamates of the manufacturing apparatus, and an isocyanate production apparatus	JP2012520339	2011-05-19	JP5487303B2	2014-05-07	孝二高松; 聡加藤; 偉志福田; 哲也中野; 祐明佐々木

20	Compounds and methods of inhibiting the phosphodiesterase ▲ iv ▼	JP52185296	1996-01-11	JP2001520629A	2001-10-30	カヴァラ，デビッド，ジェイ．; チェイシン，マーク; ドルビー，ロイド
(57)【要約】有効なＰＤＥ IV阻害剤である新規化合物を開示する。該化合物は、テオフィリンまたはロリプラムと比較して改善されたＰＤＥ IV阻害、およびＰＤＥ III阻害に関して改善された選択性を有する。本発明のいくつかの態様においては、前記化合物はＰＤＥＶ阻害も示す。該化合物を含む薬剤組成物および治療方法も開示する。

1 2 3

该功能需要专业版企业版VIP权限，您可以：